linjc16/ctgov huggingface dataset:
Outcomes Following Medical or Surgical Management of Endocarditis

Study Overview
=================
Brief Summary
-----------------
Infective endocarditis is a rare disease, and while there have been several large reviews of the incidence of endocarditis in the pediatric patient population, relatively little has been published regarding the short and medium-term outcomes following medical and surgical therapy for this disease. The goal is to compare the outcome for children treated for endocarditis with either medical management or surgery by looking at the success of these two treatment strategies. Another goal is to attempt to identify risk factors for medical management that might identify patients who would be better served by early surgery.

Detailed Description
-----------------
After identification of qualified subjects, the families of surviving patients will be mailed a package containing a cover letter explaining the study, a consent form, an assent form if applicable, a questionnaire (designed to evaluate longer-term outcome measures including the occurrence of recurrent endocarditis, late surgical intervention or the need for re-operations) and a self addressed stamped envelope to be used to return the consents and the questionnaire. The data will then be entered into a database and analyzed.

Official Title
-----------------
A Review of Outcomes Following Medical or Surgical Management of Endocarditis

Conditions
-----------------
Endocarditis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients discharged from Children's Healthcare of Atlanta at Egleston with a discharge diagnosis of endocarditis or those who underwent surgery with a preoperative diagnosis of endocarditis. Admitted to the hospital between January 1, 1984 - December 31, 2004, inclusive. Signed informed consent. Exclusion Criteria: Patients who do not have documented endocarditis based upon microbiology and echocardiography criteria.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pediatric, cardiology
Functional Neuroimaging of Cortical Plasticity in the Human Visual System

Study Overview
=================
Brief Summary
-----------------
The study's objective is to measure changes in human visual cortex organization that may arise as a result of injury to the visual pathways. Subjects with retinal or cortical injury will be studied and compared to appropriate controls. Functional magnetic resonance imaging methods are used to monitor cortical topography in time. The main aims of the study are to determine: 1) what are the patterns of cortical reorganization that are seen spontaneously after injury, and 2) whether rehabilitative training can promote adaptive reorganization enhancing recovery.

Official Title
-----------------
Functional Neuroimaging of Cortical Plasticity in the Human Visual System

Conditions
-----------------
Stroke, Blindness, Vision

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable lesion of the visual pathways resulting in a visual field scotoma. Exclusion Criteria: Inability to undergo magnetic resonance imaging, Inability to comply with basic instructions, Inability to perform the behavioral tasks required, Patients with chronic progressive neurological or psychiatric disorders, Patients that are pregnant, or breast feeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
plasticity, reorganization, cortical, fMRI, rehabilitation
Case Series Study of Biliary Tract Cancer Patients in Japan

Study Overview
=================
Brief Summary
-----------------
To assess the difference of prognosis between unresectable and recurrent biliary tract cancer and evaluate prognostic factors.

Detailed Description
-----------------
Most patients of biliary tract cancer have advanced disease at diagnosis and often relapse despite surgery. Combination therapy of gemcitabine and cisplatin could be a standard therapy for this kind of cancer with the evidence of phase III study compared with gemcitabine alone. However the prognosis and the tolerability of chemotherapy in the patients with recurrent biliary tract cancer after radical resection might differ from those of unresectable biliary tract cancer, because the dose intensity of chemotherapy can be influenced by adjuvant chemotherapy and/or hepatic resection.

Official Title
-----------------
Retrospective Analysis of the Difference of Prognosis Between Unresectable and Recurrent Biliary Tract Cancer

Conditions
-----------------
Biliary Tract Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Unresectable or recurrent biliary tract cancer Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| One year survival rate |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival time |  | 3 years | 
| Number of participants with adverse events |  | 3 years | 
| Progression free survival |  | 3 years |
Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse

Study Overview
=================
Brief Summary
-----------------
The main of this study is to assess the feasibility of a patients follow-up visit receiving trastuzumab subcutaneous by Advanced Practice Nurse.

Official Title
-----------------
Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse - TIPA

Conditions
-----------------
Breast Neoplasms

Intervention / Treatment
-----------------
* Other: Advanced Practice Nurse consultation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient care at the Cancer Institute Lucien Neuwirth Patient aged over 18 years Patient with breast cancer overexpressing HER2 adjuvant Patient having finished their chemotherapy treatment with IV followed the oncologist day hospital Patient under Trastzumab subcutaneously Patient affiliated or entitled to a social security scheme (mandatory requirement for all studies) Exclusion Criteria: Refusal to participate, most patient protected under guardianship. Patient in inability to understand the course of the study Patient with documented history of cognitive or psychiatric disorders. Patients pregnant or lactating Patients under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: consultation by Advanced Practice Nurse.<br>During consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist. | Other: Advanced Practice Nurse consultation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of consultation requiring a medical advice between IPA and oncologist | Estimate the correlation between the IPA and the oncologist about whether or not a medical opinion during the consultation | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of consultations delegated to the IPA | The oncologist estimate the percentage of consultations can be delegated to the IPA | 1 year | 
| Physician satisfaction questionnaire | Physician satisfaction questionnaire of the delegation of his consultations to the IPA | 1 year |
Quality of Postpartum Cesarean Recovery Score Validity Reliability

Study Overview
=================
Brief Summary
-----------------
In order to provide the best care of patients after cesarean section, to help solve all their biopsychosocial problems in the recovery process, and to shorten the hospitalization period, it should be measured with appropriate measurement tools for various evaluations. The Scale of Post-cesarean Healing Quality You will provide in adapting the ObsQoR-11 questionnaire to Turkish.

Detailed Description
-----------------
In order to provide the best care of patients after cesarean section, to help solve all their biopsychosocial problems in the recovery process, and to shorten the hospitalization period, it should be measured with appropriate measurement tools for various evaluations. We will provide the Scale of Post-Cesarean Healing Quality in adapting the ObsQoR-11 questionnaire to Turkish.It is important to define well the recovery after cesarean section.

Official Title
-----------------
Quality of Postpartum Cesarean Recovery Score Validity Reliability

Conditions
-----------------
Failed VBAC (Vaginal Birth After Cesarean)

Intervention / Treatment
-----------------
* Procedure: cesarean section women


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be Over 18 age, Must be literate women, Must be no neurological disease Exclusion Criteria: Must be unwilling to participate in the study Must be under 18 years old women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: cesarean section women|The test will be applied to women who have had a cesarean section and the Turkish validity and reliability of the scale will be determined according to the answers given.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of Postpartum Cesarean Recovery Score validity reliability | Measuring early recovery after cesarean section | July 2022-October 2022 | 
| obstetric qualityof- recovery score (ObsQoR-11) | Women were approached while in the postnatal ward 24 h after CS and asked to complete the ObsQoR-11K questionnaire and to choose a point in the 100-mm numeric rating scale (NRS) to evaluate global health status. Women rated each recovery item using an 11-point numerical Likert scale (0 = strongly negative; 10 = strongly positive). Global health status was measured using NRS indicated by a 100 mm line (0 = 'worst imaginable health status' and 'sad' face; 100 = 'best imaginable health status' and 'happy' face). | About six mount |
Ten-Year Outcomes of PRE-COMBAT Trial

Study Overview
=================
Brief Summary
-----------------
This study evaluates Ten-Year Outcomes of PREmier of Randomized Comparison of Sirolimus-Eluting Stent Implantation Versus Coronary Artery Bypass Surgery for Unprotected Left Main Coronary Artery Stenosis(PRECOMBAT trial).

Detailed Description
-----------------
This study is an extended one of PRECOMBAT trial.

Official Title
-----------------
Ten-Year Outcomes of PREmier of Randomized Comparison of Sirolimus-Eluting Stent Implantation Versus Coronary Artery Bypass Surgery for Unprotected Left Main Coronary Artery Stenosis: PRE-COMBAT Trial

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Procedure: Percutaneous coronary intervention
* Procedure: coronary artery bypass graft


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject group enrolled in PRECOMBAT trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Left main coronary disease<br> | Procedure: Percutaneous coronary intervention<br>* Using sirolimus eluting stent<br>Procedure: coronary artery bypass graft<br>* coronary artery bypass graft<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite outcome | The composite of death, myocardial infarction, and revascularization. Patients who have experienced any one of the following events are considered to have experienced the composite outcome: death, myocardial infarction, and revascularization | 10 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality |  | 10 year | 
| Cardiac death |  | 10 year | 
| Myocardial infarction |  | 10 year | 
| Cerebrovascular accident |  | 10 year | 
| Target vessel revascularization |  | 10 year | 
| Target lesion revascularization |  | 10 year | 
| Stent thrombosis |  | 10 year | 
| Binary restenosis in both in-stent and in-segment |  | 10 year | 
| Graft reocclusion rate |  | 10 year | 
| Graft patency rate |  | 10 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PCI, CABG, Left main
Hypnosis vs Midazolam for Sedation for TEE

Study Overview
=================
Brief Summary
-----------------
Most of the reports on hypnosis in the literature have focused on pain control during minor operations. With this study we aimed to evaluate the role of hypnosis on sedation for transesophageal echocardiography and compare it with commonly used sedative midazolam.

Official Title
-----------------
Hypnosis for Sedation in Transesophageal Echocardiography: Comparison With Midazolam

Conditions
-----------------
Clinical Indications for Transesophageal Echocardiography

Intervention / Treatment
-----------------
* Drug: Midazolam
* Other: hypnotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: indications for TEE American Society of Anesthesiology (ASA) physical status I-III Exclusion Criteria: mental illness, psychotropic medication use, hypersensitivity to drugs a body mass index over 30.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| midazolam<br> | Drug: Midazolam<br>* The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.<br>|
| hypnosis<br> | Other: hypnotherapy<br>* A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sedative effects of hypnotherapy and the drug midazolam indicated by anxiety scores and bispectral index (BIS) monitoring |  | during transesophageal echocardiography | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measurement of alertness after sedation with continuous performance test (CPT) |  | the same time frame |
Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Photo Evaluation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd PHDETINLYN Tangerine Mix (Lactic Acid).

Official Title
-----------------
Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)

Conditions
-----------------
Hygiene

Intervention / Treatment
-----------------
* Drug: Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Age between 18 and 60 years old; Phototype Skin II and III; Integral skin test in the region; Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; Exclusion criteria: Lactation or gestation Use of Antiinflammatory and/or immunossupression drugs 15 days before the selection; Diseases which can cause immunity decrease, such as HIV, diabetes; Use of drug photosensitizer; History of sensitivity or irritation for topic products; Active cutaneous disease which can change the study results; History of photodermatosis active; Family or personal antecedent of cutaneous photo induced neoplasias; Presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and queratoses actinium; Intense solar exposure in the study area; Use of new drugs or cosmetics during the study;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix) | Drug: Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)<br>* Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. |  | Throughout the study | 
| The sensibility will be evaluated according to the skin type. |  | Throughout the study |
Socio-aesthetic Intervention on Body Image and Quality of Life in Women With Breast Cancer.

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the impact of a socio-aesthetic intervention on body image and quality of life in post-surgical patients with mastectomy or tumorectomy for breast cancer.Two groups of randomized subjects were constituted. Patients of the experimental group received 2 or 3 aesthetic care during the first post-surgical week, whereas those of the control group not. Body image, quality of life and diverse other personality variables were assessed at three different times: surgical operation day before, exit day before of hospitalization and three months afterwards. Our general hypothesis is that subjects who receive aesthetic care report levels significantly higher of corporal satisfaction and of quality of life at the end of the hospitalization and three months later than patients of the control group.

Official Title
-----------------
Impact of a Socio-aesthetic Intervention on Body Image and Quality of Life in Patients With Mastectomy or Tumorectomy for Breast Cancer.

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Behavioral: Aesthetic care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: First diagnosis of cancer and first surgical treatment for cancer Diagnosis of breast cancer Exclusion criteria: Psychiatric antecedents Inclusion in another psychosocial research

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Aesthetic care|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aesthetic care,, Mastectomy,, Breast cancer,, Quality of life,, Body image,, Psychological adjustment